RxDoctor Payments Data

Faraz Tyeb, DO

Psychiatry · Ephrata, PANPI 1639458417

Payments from drug & device makers

$14,018in general payments, 2019–2025

Across 396 payments — averaging $35.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$574
  • Sunovion Pharmaceuticals Inc.$572
  • Neurocrine Biosciences, Inc.$494
  • Axsome Therapeutics, Inc.$369
  • plus $2K from 9 others

What the payments were for

  • Speaking & faculty fees$7,64055%
  • Travel & lodging$1481%
  • Food & beverage$5,79141%
  • Education$4383%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,018 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$16,312
Medicare patients
37
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl44$62,921
LatudaLurasidone Hcl14$22,691
TrintellixVortioxetine Hydrobromide34$16,561
Lurasidone Hcl22$9,889
Fluphenazine Decanoate17$2,408
Aripiprazole59$2,288
Vilazodone Hcl14$1,671
Prazosin Hcl65$1,238
Duloxetine Hcl40$1,056
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$964
Clozapine18$907
Bupropion XlBupropion Hcl56$901
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$875
Trazodone Hcl100$857
Lamotrigine87$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$8,795$62,92144 claims
Sunovion Pharmaceuticals Inc.Latuda$572$22,69114 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$128$16,56134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Ephrata

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →